Biosimilar Resources

Biosimilars are biologic medicines that are highly similar to already approved reference products, offering comparable safety, efficacy, and quality at a reduced cost. Our resources provide information on the use, benefits, and regulatory guidelines of biosimilars to help healthcare professionals improve patient access and manage treatment costs effectively. To learn more about biosimilars and biologics visit AMCP's Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) at bbcic.org.

Featured Resources

See All in Biosimilars
AMCP Podcast Series Featured Episode
Podcast

The Buzz Around Biosimilars: AMCP’s Actions for 2023

2023 will be a pivotal year for biosimilar success or failure. Health care expert Fred Goldstein sits down with Stanton Mehr of Biosimilars Review & Report, to discuss what lies in store for biosimilars and AMCP’s biosimilar initiatives this year.
AMCP Podcast Series Featured Episode
Podcast

Humira Biosimilars are Here! What Now?

Health care expert Fred Goldstein sits down with Melissa Andel, principal and founder of CommonHealth Solutions, to discuss the long-awaited launch of Humira biosimilars and what Amgen’s pricing strategy means for patients and payers.
Webinars

Bracing for the Impact of Biosimilars: Navigating Terrain in the U.S. Market Landscape

  • Tuesday, Jun. 11, 2024 at 2-3pm ET
Letters, Statements & Analysis

AMCP Submits Comments to the Ohio Senate Health and Human Services Committee, Opposing Sub. HB No. 505, a Bill Concerning Biosimilars

The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to comment on Sub. H.B. No. 505 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists. AMCP is opposed to this legislation as it places an undue burden on the dispensing of interchangeable biological products once approved by the FDA.
Biosimilars
Letters, Statements & Analysis

AMCP Submits Comments on Hawaii HB 254 Concerning Biosimilars

The Academy of Managed Care Pharmacy (AMCP) is writing to express its opposition to certain provisions of H.B. No. 254. AMCP opposes the practitioner notification requirements, which would place an unnecessary burden on the substitution of an interchangeable biological drug product. In addition, AMCP also opposes the new definition of “interchangeable biological product” included in the bill, which is not consistent with the Food and Drug Administration (FDA) definition.
Biosimilars
Meeting Proceedings & Findings

Biosimilars - Ready, Set, Launch

Partnership Forum: Industry leaders gathered June 10-11, 2015 to address the current readiness of MCOs to optimize biosimilars and identify gaps and resources needed.
Biosimilars
Resource

Health Plan Executive Forum Panel #3: Specialty Pharmacy & Biosimilars - Improving Population Health

Video from the December 2014 Health Plan Executive Forum featuring Steven G. Avey, RPh, MS, FAMCP, Vice President, Specialty Programs, MedImpact Healthcare Systems, Inc.; Alan M. Lotvin, MD, Executive Vice President, CVS/specialty, CVS Health; Thomas Parry, PhD, President, Integrated Benefits Institute; and Margaret Rehayem, MA, Senior Director of Strategic Intiiatives and Communications, Midwest Business Group on Health.
Biosimilars, Specialty Pharmacy, Biosimilars